Fereshteh Shiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fereshteh Shiri has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Jahan Bakhsh Ghasemi
Chemistry Faculty, School of Sciences, University of Tehran, Tehran, Iran
8 shared publications Pouya Karimi
Department of Chemistry, Faculty of Science, University of Zabol, Zabol, Iran
5 shared publicationsSomaye Shahraki
Department of Chemistry, University of Zabol, Zabol 9861335856, Iran
5 shared publications- Somaye Shahraki
Department of Chemistry, University of Zabol, Zabol, Iran
5 shared publications Maryam Salahinejad
Nuclear Science and Technology Research Institute, Tehran, Iran
4 shared publicationsShahin Ahmadi
Department of Chemistry, TeMS.C., Islamic Azad University, Tehran, Iran
4 shared publications
Latest Publications
- Open Access
- 26 February 2026
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 312, 119948
A global Quasi-SMILES model based on the Monte Carlo algorithm for assessing the multi-organism aquatic ecotoxicity of personal care products
- 26 February 2026
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 312, 119948
Open AccessA global Quasi-SMILES model based on the Monte Carlo algorithm for assessing the multi-organism aquatic ecotoxicity of personal care products
- 25 November 2025
- Published by Elsevier in Food Chemistry
- Vol. 498 (Pt 2) , 147208
pH-switchable vortex-assisted liquid-liquid microextraction using hydrophobic eutectic solvents for the extraction of phthalate esters from water, fruit juice, and milk samples
- 25 November 2025
- Published by Elsevier in Food Chemistry
- Vol. 498 (Pt 2) , 147208
pH-switchable vortex-assisted liquid-liquid microextraction using hydrophobic eutectic solvents for the extraction of phthalate esters from water, fruit juice, and milk samples
- Open Access
- 4 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-24
Identification of potential PI3Kγ inhibitors among FDA approved drugs using integrated computational and quantum chemical approaches
Phosphoinositide 3-kinase gamma (PI3Kγ) is recognized as a promising target for inhibiting the activity of cancer cells, leading to increased efforts to develop PI3Kγ inhibitors as potential cancer therapies. In this research, Quantitative Structure–Activity Relationship (QSAR) modeling was performed using CORAL software on a dataset comprising 243 PI3Kγ inhibitor compounds. The model enabled the prediction of the endpoint (pIC50) for different populations of chemical compounds targeting the PI3Kγ receptor. It demonstrated high predictive accuracy for split 1 and TF3, achieving R2val = 0.8003, Q2 = 0.7807, and MAE = 0.3410, using the optimized parameters WIIC = 0.2 and WCII = 0.5. A screening of FDA-approved drugs, which were not part of our dataset, identified 11 potential candidates as PI3Kγ receptor ligands (predicted pIC50 ≥ 9). A literature review revealed that 8 of these compounds had previously been evaluated for PI3K receptor interactions. Among them, Epirubicin, Doxorubicin, and Daunorubicin; all anthracycline chemotherapy agents; are known to inhibit cancer progression by slowing or halting cell growth. Molecular dynamics simulations further validated the QSAR screening results, confirming that Epirubicin forms the most stable and tightly bound complex with PI3Kγ, with ΔGbind values of –3.81 kcal/mol for PI3Kγ–M192 and –4.47 kcal/mol for PI3Kγ–Epirubicin. These findings indicate that the QSAR model could function as a targeted screening tool, facilitating the identification of drugs with strong affinity for the PI3Kγ receptor, and ultimately improving the hit rate compared to random screening approaches.
- 4 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-24
Open AccessIdentification of potential PI3Kγ inhibitors among FDA approved drugs using integrated computational and quantum chemical approaches
Phosphoinositide 3-kinase gamma (PI3Kγ) is recognized as a promising target for inhibiting the activity of cancer cells, leading to increased efforts to develop PI3Kγ inhibitors as potential cancer therapies. In this research, Quantitative Structure–Activity Relationship (QSAR) modeling was performed using CORAL software on a dataset comprising 243 PI3Kγ inhibitor compounds. The model enabled the prediction of the endpoint (pIC50) for different populations of chemical compounds targeting the PI3Kγ receptor. It demonstrated high predictive accuracy for split 1 and TF3, achieving R2val = 0.8003, Q2 = 0.7807, and MAE = 0.3410, using the optimized parameters WIIC = 0.2 and WCII = 0.5. A screening of FDA-approved drugs, which were not part of our dataset, identified 11 potential candidates as PI3Kγ receptor ligands (predicted pIC50 ≥ 9). A literature review revealed that 8 of these compounds had previously been evaluated for PI3K receptor interactions. Among them, Epirubicin, Doxorubicin, and Daunorubicin; all anthracycline chemotherapy agents; are known to inhibit cancer progression by slowing or halting cell growth. Molecular dynamics simulations further validated the QSAR screening results, confirming that Epirubicin forms the most stable and tightly bound complex with PI3Kγ, with ΔGbind values of –3.81 kcal/mol for PI3Kγ–M192 and –4.47 kcal/mol for PI3Kγ–Epirubicin. These findings indicate that the QSAR model could function as a targeted screening tool, facilitating the identification of drugs with strong affinity for the PI3Kγ receptor, and ultimately improving the hit rate compared to random screening approaches.
- Open Access
- 25 July 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (33) , 27033-27045
Synergistic, theoretical, and experimental study of the interaction of a tri-heterometallic polymer with bovine liver catalase
Reactive oxygen species (ROS) modulate redox balance and cellular processes such as proliferation, angiogenesis, metabolism, immune modulation, and metastasis. Metal-based polymeric complexes have shown potential in disrupting oxidative pathways relevant to tumor development. A comprehensive investigation was conducted on the interaction between a Cu/Mn/Na polymer and catalase, as well as its cytotoxic behavior. The compound exhibited notable antioxidant properties, achieving 61.2% inhibition of the DPPH radical at 125 μM after 60 min. Additionally, the polymer enhanced bovine liver catalase (BLC) activity by up to 138.9% at 7.7 × 10−6 M, with a moderate binding constant in the range of 104 M−1. Fluorescence analyses revealed a static quenching mechanism, and molecular docking revealed hydrogen bonding and van der Waals forces to be the key stabilizing interactions. Conformational analyses demonstrated significant structural alterations in BLC upon polymer interaction. The MTT assay revealed considerable antiproliferative effects against colon carcinoma (HCT116) cells, with activity comparable with that of cisplatin at higher concentrations. Importantly, unlike cisplatin, the polymer exhibited minimal toxicity towards normal cells (NIH/3T3), suggesting its potential as an anticancer agent. These findings indicate the potential of the polymer as a redox-modulating therapeutic agent with promising anticancer properties.
- 25 July 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (33) , 27033-27045
Open AccessSynergistic, theoretical, and experimental study of the interaction of a tri-heterometallic polymer with bovine liver catalase
Reactive oxygen species (ROS) modulate redox balance and cellular processes such as proliferation, angiogenesis, metabolism, immune modulation, and metastasis. Metal-based polymeric complexes have shown potential in disrupting oxidative pathways relevant to tumor development. A comprehensive investigation was conducted on the interaction between a Cu/Mn/Na polymer and catalase, as well as its cytotoxic behavior. The compound exhibited notable antioxidant properties, achieving 61.2% inhibition of the DPPH radical at 125 μM after 60 min. Additionally, the polymer enhanced bovine liver catalase (BLC) activity by up to 138.9% at 7.7 × 10−6 M, with a moderate binding constant in the range of 104 M−1. Fluorescence analyses revealed a static quenching mechanism, and molecular docking revealed hydrogen bonding and van der Waals forces to be the key stabilizing interactions. Conformational analyses demonstrated significant structural alterations in BLC upon polymer interaction. The MTT assay revealed considerable antiproliferative effects against colon carcinoma (HCT116) cells, with activity comparable with that of cisplatin at higher concentrations. Importantly, unlike cisplatin, the polymer exhibited minimal toxicity towards normal cells (NIH/3T3), suggesting its potential as an anticancer agent. These findings indicate the potential of the polymer as a redox-modulating therapeutic agent with promising anticancer properties.
- 2 March 2025
- Published by Springer Nature
- p. 3-26
Introduction to Machine Learning for Predictive Modeling II
- 2 March 2025
- Published by Springer Nature
- p. 3-26
Introduction to Machine Learning for Predictive Modeling II
- Open Access
- 2 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-14
Synthesis, biological evaluation and in silico study of 4-(benzo[d]thiazole-2-yl) phenols based on 4-hydroxy coumarin as acetylcholinesterase inhibitors
Alzheimer’s disease, characterized by cognitive decline and memory loss, is associated with decreased acetylcholine levels due to acetylcholinesterase (AChE) activity. Compounds containing a coumarin heterocyclic core coupled with thiazole exhibit excellent acetylcholinesterase inhibitory activity. In this work, we designed and synthesized a series of 4-(benzo[d]thiazole-2-yl) phenols based on 4-hydroxycoumarin. The compounds were synthesized and their inhibitory activities were evaluated through in vitro biological assays. Of the compounds investigated, 3i exhibited the strongest inhibitory activity, with an IC50 value of 2.7 µM. Molecular docking and molecular dynamics simulations were employed to elucidate the binding interactions and stability of the synthesized compounds with AChE. The results demonstrated promising inhibitory activity, suggesting potential therapeutic applications for Alzheimer’s disease. This research contributes to the development of coumarin-based heterocyclic compounds as effective AChE inhibitors.
- 2 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-14
Open AccessSynthesis, biological evaluation and in silico study of 4-(benzo[d]thiazole-2-yl) phenols based on 4-hydroxy coumarin as acetylcholinesterase inhibitors
Alzheimer’s disease, characterized by cognitive decline and memory loss, is associated with decreased acetylcholine levels due to acetylcholinesterase (AChE) activity. Compounds containing a coumarin heterocyclic core coupled with thiazole exhibit excellent acetylcholinesterase inhibitory activity. In this work, we designed and synthesized a series of 4-(benzo[d]thiazole-2-yl) phenols based on 4-hydroxycoumarin. The compounds were synthesized and their inhibitory activities were evaluated through in vitro biological assays. Of the compounds investigated, 3i exhibited the strongest inhibitory activity, with an IC50 value of 2.7 µM. Molecular docking and molecular dynamics simulations were employed to elucidate the binding interactions and stability of the synthesized compounds with AChE. The results demonstrated promising inhibitory activity, suggesting potential therapeutic applications for Alzheimer’s disease. This research contributes to the development of coumarin-based heterocyclic compounds as effective AChE inhibitors.
- Open Access
- 3 October 2024
- Published by Springer Nature in BMC Chemistry
- Vol. 18 (1) , 1-20
SMILES-based QSAR virtual screening to identify potential therapeutics for COVID-19 by targeting 3CLpro and RdRp viral proteins
The COVID-19 pandemic has prompted the medical systems of many countries to develop effective treatments to combat the high rate of infection and death caused by the disease. Within the array of proteins found in SARS-CoV-2, the 3 chymotrypsin-like protease (3CLpro) holds significance as it plays a crucial role in cleaving polyprotein peptides into distinct functional nonstructural proteins. Meanwhile, RNA-dependent RNA polymerase (RdRp) takes center stage as the key enzyme tasked with replicating the viral genomic RNA within host cells. These proteins, 3CLpro and RdRp, are deemed optimal subjects for QSAR modeling due to their pivotal functions in the viral lifecycle. In this study, SMILES-based QSAR classification models were developed for a dataset of 2377 compounds that were defined as either active or inactive against 3CLpro and RdRp. Pharmacophore (PH4) and QSAR modeling were used for the virtual screening on 60.2 million compounds including ZINC, ChEMBL, Molport, and MCULE databases to identify new potent inhibitors against 3CLpro and RdRp. Then, a filter was established based on typical molecular characteristics to identify drug-like molecules. The molecular docking was also performed to evaluate the binding affinity of 156 AND 51 potential inhibitors to 3CLpro and RdRp, respectively. Among the 15 hits identified based on molecular docking scores, M3, N2, and N4 were identified as promising inhibitors due to their good synthetic accessibility scores (3.07, 3.11, and 3.29 out of 10 for M3, N2, and N4 respectively). These compounds contain amine functional groups, which are known for their crucial role in the binding interactions between drugs and their targets. Consequently, these hits have been chosen for further biological assay studies to validate their activity. They may represent novel 3CLpro and RdRp inhibitors possessing drug-like properties suitable for COVID-19 therapy.
- 3 October 2024
- Published by Springer Nature in BMC Chemistry
- Vol. 18 (1) , 1-20
Open AccessSMILES-based QSAR virtual screening to identify potential therapeutics for COVID-19 by targeting 3CLpro and RdRp viral proteins
The COVID-19 pandemic has prompted the medical systems of many countries to develop effective treatments to combat the high rate of infection and death caused by the disease. Within the array of proteins found in SARS-CoV-2, the 3 chymotrypsin-like protease (3CLpro) holds significance as it plays a crucial role in cleaving polyprotein peptides into distinct functional nonstructural proteins. Meanwhile, RNA-dependent RNA polymerase (RdRp) takes center stage as the key enzyme tasked with replicating the viral genomic RNA within host cells. These proteins, 3CLpro and RdRp, are deemed optimal subjects for QSAR modeling due to their pivotal functions in the viral lifecycle. In this study, SMILES-based QSAR classification models were developed for a dataset of 2377 compounds that were defined as either active or inactive against 3CLpro and RdRp. Pharmacophore (PH4) and QSAR modeling were used for the virtual screening on 60.2 million compounds including ZINC, ChEMBL, Molport, and MCULE databases to identify new potent inhibitors against 3CLpro and RdRp. Then, a filter was established based on typical molecular characteristics to identify drug-like molecules. The molecular docking was also performed to evaluate the binding affinity of 156 AND 51 potential inhibitors to 3CLpro and RdRp, respectively. Among the 15 hits identified based on molecular docking scores, M3, N2, and N4 were identified as promising inhibitors due to their good synthetic accessibility scores (3.07, 3.11, and 3.29 out of 10 for M3, N2, and N4 respectively). These compounds contain amine functional groups, which are known for their crucial role in the binding interactions between drugs and their targets. Consequently, these hits have been chosen for further biological assay studies to validate their activity. They may represent novel 3CLpro and RdRp inhibitors possessing drug-like properties suitable for COVID-19 therapy.
- Open Access
- 11 June 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (25) , 27071-27084
Experimental and Theoretical Approaches to Monitor the Behavior of Bovine Liver Catalase in Interaction with a Binuclear Bismuth Complex
Here, the antioxidant potency of a binuclear Bi(III) complex {[Bi2(μ-ox)(dipic)2(H2O)2 (taa)2].H2O, where ox2– = oxalato, dipic2– = pyridine 2,6-dicarboxylato, and taa = thiourea} was evaluated using the •DPPH assay. It was demonstrated that the Bi complex exhibited a high ability to inhibit DPPH free radicals. The binding mechanism of the complex with bovine liver catalase (BLC) was also investigated, revealing structural and activity changes in the enzyme in the presence of the complex. The catalase activity in the decomposition of hydrogen peroxide increased in the presence of the Bi complex, reaching 39.8% higher than its initial activity at a concentration of 7.77 × 10–6 M. The complex exhibited a relatively high affinity for BLC, with Kb values of 3.98, 0.13, and 0.09 × 105 M–1 at 303, 310, and 317 K, respectively. The mechanisms involved in the interaction were hydrogen bonding and van der Waals interactions, as validated through molecular docking simulations. Synchronous fluorescence showed that tryptophan was more affected by enzyme–complex interactions than tyrosine. In addition, a cell viability test using the MTT method revealed that at its highest concentration, the Bi complex caused a decrease in the number of cells below 50% compared to the control, while cisplatin showed negative effects at all concentrations. These findings suggest that the Bi complex has the potential to be developed as a promising candidate for BLC-related therapeutic target therapy.
- 11 June 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (25) , 27071-27084
Open AccessExperimental and Theoretical Approaches to Monitor the Behavior of Bovine Liver Catalase in Interaction with a Binuclear Bismuth Complex
Here, the antioxidant potency of a binuclear Bi(III) complex {[Bi2(μ-ox)(dipic)2(H2O)2 (taa)2].H2O, where ox2– = oxalato, dipic2– = pyridine 2,6-dicarboxylato, and taa = thiourea} was evaluated using the •DPPH assay. It was demonstrated that the Bi complex exhibited a high ability to inhibit DPPH free radicals. The binding mechanism of the complex with bovine liver catalase (BLC) was also investigated, revealing structural and activity changes in the enzyme in the presence of the complex. The catalase activity in the decomposition of hydrogen peroxide increased in the presence of the Bi complex, reaching 39.8% higher than its initial activity at a concentration of 7.77 × 10–6 M. The complex exhibited a relatively high affinity for BLC, with Kb values of 3.98, 0.13, and 0.09 × 105 M–1 at 303, 310, and 317 K, respectively. The mechanisms involved in the interaction were hydrogen bonding and van der Waals interactions, as validated through molecular docking simulations. Synchronous fluorescence showed that tryptophan was more affected by enzyme–complex interactions than tyrosine. In addition, a cell viability test using the MTT method revealed that at its highest concentration, the Bi complex caused a decrease in the number of cells below 50% compared to the control, while cisplatin showed negative effects at all concentrations. These findings suggest that the Bi complex has the potential to be developed as a promising candidate for BLC-related therapeutic target therapy.